Literature DB >> 25700911

Thymoma related myasthenia gravis in humans and potential animal models.

Alexander Marx1, Stefan Porubsky2, Djeda Belharazem2, Güher Saruhan-Direskeneli3, Berthold Schalke4, Philipp Ströbel5, Cleo-Aron Weis6.   

Abstract

Thymoma-associated Myasthenia gravis (TAMG) is one of the anti-acetylcholine receptor MG (AChR-MG) subtypes. The clinico-pathological features of TAMG and its pathogenesis are described here in comparison with pathogenetic models suggested for the more common non-thymoma AChR-MG subtypes, early onset MG and late onset MG. Emphasis is put on the role of abnormal intratumorous T cell selection and activation, lack of intratumorous myoid cells and regulatory T cells as well as deficient expression of the autoimmune regulator (AIRE) by neoplastic thymic epithelial cells. We review spontaneous and genetically engineered thymoma models in a spectrum of animals and the extensive clinical and immunological overlap between canine, feline and human TAMG. Finally, limitations and perspectives of the transplantation of human and murine thymoma tissue into nude mice, as potential models for TAMG, are addressed.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AIRE; APS-I; Animal model; BUF/Mna; Cat; Dog; Horse; Myasthenia gravis; Rat; Thymoma; Tiger

Mesh:

Year:  2015        PMID: 25700911     DOI: 10.1016/j.expneurol.2015.02.010

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  19 in total

Review 1.  The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes.

Authors:  Alexander Marx; John K C Chan; Jean-Michel Coindre; Frank Detterbeck; Nicolas Girard; Nancy L Harris; Elaine S Jaffe; Michael O Kurrer; Edith M Marom; Andre L Moreira; Kiyoshi Mukai; Attilio Orazi; Philipp Ströbel
Journal:  J Thorac Oncol       Date:  2015-10       Impact factor: 15.609

Review 2.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

3.  Multi-color flow cytometry for evaluating age-related changes in memory lymphocyte subsets in dogs.

Authors:  Sita S Withers; Peter F Moore; Hong Chang; Jin W Choi; Stephen J McSorley; Michael S Kent; Arta M Monjazeb; Robert J Canter; William J Murphy; Ellen E Sparger; Robert B Rebhun
Journal:  Dev Comp Immunol       Date:  2018-05-31       Impact factor: 3.636

4.  Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis.

Authors:  Estefanía Torres-Vega; Nuria Mancheño; Arantxa Cebrián-Silla; Vicente Herranz-Pérez; María J Chumillas; Germán Moris; Bastien Joubert; Jérôme Honnorat; Teresa Sevilla; Juan J Vílchez; Josep Dalmau; Francesc Graus; José Manuel García-Verdugo; Luis Bataller
Journal:  Neurology       Date:  2017-03-01       Impact factor: 9.910

5.  Thymic pathologies in myasthenia gravis: a preoperative assessment of CAT scan and nuclear based imaging.

Authors:  Berit Jordan; Juliane Kellner; Karin Jordan; Manfred Bähre; Curd Behrmann; Stephan Zierz
Journal:  J Neurol       Date:  2016-01-25       Impact factor: 4.849

Review 6.  Advances in autoimmune myasthenia gravis management.

Authors:  Shuhui Wang; Iva Breskovska; Shreya Gandhy; Anna Rostedt Punga; Jeffery T Guptill; Henry J Kaminski
Journal:  Expert Rev Neurother       Date:  2018-07-04       Impact factor: 4.618

Review 7.  Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms.

Authors:  William D Phillips; Angela Vincent
Journal:  F1000Res       Date:  2016-06-27

8.  Gene-Specific Methylation Analysis in Thymomas of Patients with Myasthenia Gravis.

Authors:  Angela Lopomo; Roberta Ricciardi; Michelangelo Maestri; Anna De Rosa; Franca Melfi; Marco Lucchi; Alfredo Mussi; Fabio Coppedè; Lucia Migliore
Journal:  Int J Mol Sci       Date:  2016-12-16       Impact factor: 5.923

9.  The Cancer Genome Atlas dataset-based analysis of aberrantly expressed genes by GeneAnalytics in thymoma associated myasthenia gravis: focusing on T cells.

Authors:  Jianying Xi; Liang Wang; Chong Yan; Jie Song; Yang Song; Ji Chen; Yongjun Zhu; Zhiming Chen; Chun Jin; Jianyong Ding; Chongbo Zhao
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895

10.  Myasthenia gravis as a prognostic marker in patients with thymoma.

Authors:  Bernardo Cacho-Díaz; Karen Salmerón-Moreno; Nydia A Lorenzana-Mendoza; Julia Texcocano; Oscar Arrieta
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.